Chemistry:Darlifarnib
From HandWiki
Darlifarnib is an investigational new drug that is being developed by Kura Oncology, Inc. for the treatment of solid tumors. It is a farnesyltranstransferase inhibitor.[1][2][3]
References
- ↑ "Darlifarnib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800062546.
- ↑ "The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition". Cancer Research 86 (9): 2273–2285. May 2026. doi:10.1158/0008-5472.CAN-25-2764. PMID 41661652.
- ↑ "Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCC". Molecular Cancer Therapeutics: OF1–OF11. March 2026. doi:10.1158/1535-7163.MCT-25-0449. PMID 41881565.
 |  |
